CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 246.59 AUD 0.56% Market Closed
Market Cap: 119.4B AUD

EV/EBIT
Enterprise Value to EBIT

21.6
Current
28.1
Median
3.8
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
21.6
=
Enterprise Value
131.5B AUD
/
EBIT
3.9B USD
EBIT Growth EV/EBIT to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBIT: 19.8
21.6
14%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 562.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.2
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -544.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.5
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -313.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 625.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
18.7
2-Years Forward
EV/EBIT
16.8
3-Years Forward
EV/EBIT
14.9